141 results
Page 2 of 8
8-K
EX-99.1
80oqb1
14 Feb 19
BIOTIME PROVIDES BUSINESS UPDATE including information ON agex, ONCOCYTE and ASTERIAS
8:05am
424B3
3ik875wpg6
4 Feb 19
Prospectus supplement
5:52pm
S-4/A
5tlszux7dnv9w b6
14 Jan 19
Registration of securities issued in business combination transactions (amended)
12:00am
S-4
s1zy1mhlna a6r0tyy
4 Jan 19
Registration of securities issued in business combination transactions
5:05pm
425
9xwvr8
8 Nov 18
Business combination disclosure
9:54pm
425
EX-99.1
qvq3ojag
8 Nov 18
Business combination disclosure
6:41am
8-K
EX-99.1
170cg4h1rqjqatr5w
8 Nov 18
BioTime and ASTERIAS BIOTHERAPEUTICS enter into definitive merger agreement TO CREATE leading cell therapy company
6:41am
8-K
EX-99.1
ei3wag8gvegj ezpm
2 Aug 18
BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
4:13pm
424B5
dtiodqunaer2t8ybufw
13 Oct 17
Prospectus supplement for primary offering
12:00am
424B5
ldvd caymgkxpdq
12 Oct 17
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
08ylg dm94
30 Sep 15
Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements
12:00am
8-K
0elx4d0atk kw
30 Sep 15
Heraeus Medical GmbH and BioTime Subsidiary OrthoCyte Corporation Enter Into Exclusive Worldwide Development and Licensing Agreements
12:00am
424B5
zf8mj54mpdvn7y34m
14 Sep 15
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
xmr2h8uhk4
24 Feb 15
BioTime Announces First Patient Treated in Pivotal Clinical Trial of Renevia™ for HIV-Associated Lipoatrophy
12:00am